<DOC>
	<DOCNO>NCT00887406</DOCNO>
	<brief_summary>GSK961081 new long-acting bronchodilator develop treatment chronic obstructive pulmonary disease ( COPD ) . This study first clinical study human . The purpose study determine safety , tolerability , pharmacokinetics pharmacodynamics GSK961081 healthy male subject .</brief_summary>
	<brief_title>Study GSK961081 Healthy Volunteer Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Healthy adult male age 18 50 year . Body mass index within range 18.529.9 kilograms/meter2 ( kg/m2 ) . Forced Expiratory Volume 1 second ( FEV1 ) &lt; 80 % predict FEV1/ Forced Vital Capacity ( FVC ) ratio &lt; 0.7 Response Salbutamol define : increase sGAW &gt; 15 % predose baseline within 2 h follow administration 400 mcg Salbutamol MDI inhaler OR : documented increase sGAW &gt; 15 % predose baseline within 2 h follow administration 400 mcg Salbutamol MDI inhaler within 6 month screen . Response Ipratropium bromide define : increase sGaw &gt; 25 % predose baseline within 2 h follow 80 mcg Ipratropium bromide ; OR : documented increase sGaw &gt; 25 % predose baseline 2 h follow administration 80 mcg Ipratropium bromide within 6 month screen . A signed date write informed consent obtain subject The subject able understand comply protocol requirement , instruction protocolstated restriction . Subjects current nonsmoker use tobacco product 6month period precede screen visit pack history &gt; = 10 pack year . [ number pack year = ( number cigarette per day/20 ) x number year smoke ] Any clinically relevant abnormality identify screen medical assessment ( physical examination/medical history ) , clinical laboratory test , ECG ( 12lead Holter ) . A history breathing problem ( i.e . history asthmatic symptom ) . Screening lung function test ( FEV1 , FVC sGaw ) perform confirm normal lung function parameter . A mean QTc ( B ) QTc ( F ) value screen &gt; 430msec , 3 screen ECGs within 10 % mean , PR interval outside range 120210msec ECG suitable QT measurement ( e.g . poorly define termination T wave ) . A supine blood pressure persistently high 140/90 millimetre mercury ( mmHg ) screening . A supine mean heart rate outside range 4090 beat per minute ( bpm ) screening . The subject donate unit blood within 90 day intend donate within 90 day complete study . A history claustrophobia may tolerate plethysmography measurement . The subject currently take regular ( course ) medication whether prescribed , include vitamin herbal remedy St John 's Wort . The subject use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( ever longer ) prior first dose study medication , unless opinion Investigator Sponsor medication interfere study procedure compromise subject safety . The subject participate clinical study another New Chemical Entity ( NCE ) within past 112 day clinical study drug previous 84 day . The subject infect Hepatitis B , Hepatitis C , HIV virus . The subject positive prestudy urine cotinine/ breath carbon monoxide test , urine drug/urine alcohol screen . A minimum list drug screen include Amphetamines , Barbituates , Cocaine , Opiates , Cannabinoids Benzodiazepines . A history regular alcohol consumption exceed weekly intake alcohol great 28 unit , average daily intake great 4 unit . Are unable use Prodose AAD nebuliser device correctly . An unwillingness subject abstain sexual intercourse pregnant lactating woman ; unwillingness subject use condom/spermicide addition female partner use another form contraception IUD , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation woman could become pregnant time first dose study medication 90 day postdose . The subject history drug allergy , , opinion responsible physician , contraindicate participation . The subject history hypersensitivity Salbutamol Ipratropium bromide , subject cohort III IV , hypersensitivity betablocker . The subject low respiratory tract infection within 4 week study start</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>first time human study</keyword>
	<keyword>COPD</keyword>
	<keyword>long-acting bronchodilator</keyword>
</DOC>